Merck & Co. Inc. (MRK) Stock
NYSEMRK has an Alpha Score of 36 out of 100 (weak), computed on Oct 28, 2026 from 3 of 4 sub-scores. 57 members of Congress disclosed 171 trades in MRK since 2014: 86 purchases and 85 sales, most recently Maria Elvira Salazar (partial sale, Sep 24, 2026). 5 of the hedge funds AlphaScala tracks reported MRK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $351.84M. Company insiders reported 0 open-market buys and 17 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 115.3 and its net margin 4.8% (key statistics as of Oct 22, 2026).
What is MRK's Alpha Score?
How it works →Alpha Score of 36 reflects weak overall profile with moderate momentum, poor value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Merck & Co. Inc. (MRK)?
Most recent: Maria Elvira Salazar (partial sale, Sep 24, 2026); records start Feb 27, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Maria Elvira Salazar R-FL · House | 2026-09-24 | partial sale | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-08-19 | purchase | $15k – $50k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | sale | $15k – $50k |
| Josh Gottheimer D-NJ · House | 2026-02-04 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-12-19 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-12-18 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-11-18 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-11-13 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded MRK, with filing lags →Which hedge funds own MRK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 2.74M | $351.84M | -19% |
| Citadel Ken Griffin | 1.93M | $248.48M | -49% |
| Millennium Management Israel Englander | 561K | $72.13M | -72% |
| Point72 Steve Cohen | 380K | $48.84M | -59% |
| Bridgewater Associates Ray Dalio | 30K | $3.89M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Merck & Co. Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 13, 26 | Guindo Chirfi | EVP, Access, Policy & Comms | SELL | 10.0K | $1.4M |
| Aug 12, 26 | Deluca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 11.1K | $1.5M |
| Aug 12, 26 | Deluca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 600 | $79K |
| Aug 12, 26 | Zachary Jennifer | EVP, General Counsel | SELL | 80.3K | $10.7M |
| Aug 11, 26 | Deluca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 7.4K | $973K |
| Aug 11, 26 | Deluca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 5.4K | $718K |
| Aug 10, 26 | Deluca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 20.8K | $2.7M |
| Aug 6, 26 | Guindo Chirfi | EVP, Access, Policy & Comms | SELL | 15.0K | $2.0M |
| Aug 6, 26 | Deluca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 805 | $105K |
| Aug 6, 26 | Deluca Richard R. | EVP&Pres, Merck Animal Heallth | SELL | 4.9K | $644K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are MRK's key statistics?
Key statistics as of Oct 22, 2026
How does MRK's valuation compare with the Healthcare sector?
| Metric | MRK | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 115.3 | 27.1 | 97 |
| Net margin | 4.77% | 5.48% | 139 |
| Return on equity | 6.60% | 6.84% | 158 |
| Dividend yield (payers) | 2.87% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
What did Merck & Co. Inc.'s latest SEC filings say?
Latest 2Merck & Co. Inc. 10-K Filing Details Strategic Collaborations and Asset Acquisitions
Merck & Co. Inc. filed its 10-K for the fiscal year ending December 31, 2025. The filing outlines the company's ongoing financial structure, including long-term debt obligations and various collaborative arrangements. Merck continues to maintain significant partnerships with major pharmaceutical entities, including AstraZeneca, Eisai, Bayer AG, and Daiichi Sankyo, to develop and commercialize products such as Lynparza, Koselugo, Lenvima, and various antibody-drug conjugates. The company also reported on recent business development activities, including the acquisition of product rights from Elanco Animal Health and investments in several biotechnology firms, such as Eyebiotech Limited and Harpoon Therapeutics. The filing highlights the company's focus on research and development, with specific mentions of ongoing clinical and collaborative projects involving candidates like MK-2010, MK-4082, and MK-1045. Financial disclosures indicate a complex network of non-current assets and liabilities, reflecting the company's long-term investment strategy in pharmaceutical innovation and global manufacturing infrastructure. The report confirms the company's commitment to its core segments, Pharmaceutical and Animal Health, while navigating a landscape of patent-related considerations and collaborative revenue sharing.
- ›Acquired aqua business product rights from Elanco Animal Health in July 2024.
- ›Expanded collaborative arrangements with Daiichi Sankyo for antibody-drug conjugate development.
- ›Continued strategic partnership with AstraZeneca for Lynparza and Koselugo commercialization.
- ›Executed multiple equity investments and licensing agreements with firms including Eyebiotech and Harpoon Therapeutics.
- ›Maintained ongoing research and development focus on pipeline candidates including MK-2010 and MK-4082.
- ›Managed long-term debt portfolio including notes maturing between 2026 and 2054.
Merck & Co. Inc. Files Form 8-K Reporting Fourth Quarter and Full Year 2025 Financial Results
On February 3, 2026, Merck & Co., Inc. filed a Form 8-K with the Securities and Exchange Commission to formally announce its financial results for the fourth quarter and the full fiscal year ended December 31, 2025. The filing serves as a vehicle to incorporate by reference the company's earnings press release and additional supplemental financial information. The company provided these documents as exhibits to the report, specifically Exhibit 99.1 for the press release and Exhibit 99.2 for the supplemental data. In accordance with standard regulatory practice for earnings announcements, the information furnished under Item 2.02 of this filing is not considered filed for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. The filing confirms the company's compliance with reporting requirements regarding its operational performance and financial condition for the specified period.
- ›Merck & Co. Inc. reported financial results for the fourth quarter and full year 2025.
- ›The company provided a formal earnings press release as Exhibit 99.1.
- ›Supplemental financial information was provided as Exhibit 99.2.
- ›The filing confirms the company's adherence to SEC reporting requirements for the 2025 fiscal year end.
MRK price chart
Powered by TradingViewWhat does Merck & Co. Inc. do?
Merck & Co., Inc. operates as a leading healthcare company worldwide, focusing on human health pharmaceuticals, vaccines, and animal health products. Its portfolio includes blockbuster drugs like Keytruda for immuno-oncology, Gardasil for human papillomavirus prevention, and a range of treatments such as Welireg, ProQuad, Winrevair, Januvia, and others addressing cancer, infectious diseases, cardiometabolic conditions, and more. The company also provides veterinary solutions including Nuflor and Bovilis for livestock health management. With a substantial presence in oncology, its Keytruda leads sales contributions, complemented by vaccines targeting pediatric diseases. Merck & Co., Inc. generates significant revenue—$64.17 billion in 2024—from pharmaceuticals and vaccines, primarily in the U.S., while maintaining a diversified global footprint across consumer, business, and government sectors. Employing around 75,000 people, it plays a pivotal role in advancing treatments for chronic and infectious diseases, driving innovation in biopharmaceuticals and immunotherapy.